AbCellera Biologics ABCL
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 6th percentile, 5-year average -3.6x
Near the top of its 5-year range · 92nd percentile, 5-year average 1.7x
#3973 of 5331 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 95th percentile, 5-year average 22.4x
#4884 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.53 | – | 1.74 | 92% (pricier than usual) | #3973 of 5331 (1 = cheapest) |
| PE | -23.94 | -18.72 | -3.60 | 6% (cheaper than usual) | – |
| PS | 55.31 | 99.71 | 22.41 | 95% (pricier than usual) | #4884 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ABCL.
Sign in to join the discussion.